Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSCV for invasive Salmonella disease in healthy adults
NCT05525546Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trivalent salmonella conjugate vaccine in salmonellosis (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Frequency and Severity of Solicited Local and Systemic Adverse Events at 6 months, Frequency and Severity of Unsolicited AEs and Serious Adverse Events at 6 months and 1 more. Started Aug 2022; status: completed.
02
Drugs
trivalent salmonella conjugate vaccine
03
Conditions
salmonellosis
Beyond the preview
Go deeper on NCT05525546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525546.